R. Brachmann

747 total citations
18 papers, 610 citations indexed

About

R. Brachmann is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, R. Brachmann has authored 18 papers receiving a total of 610 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in R. Brachmann's work include Angiogenesis and VEGF in Cancer (4 papers), Cancer Treatment and Pharmacology (3 papers) and PARP inhibition in cancer therapy (3 papers). R. Brachmann is often cited by papers focused on Angiogenesis and VEGF in Cancer (4 papers), Cancer Treatment and Pharmacology (3 papers) and PARP inhibition in cancer therapy (3 papers). R. Brachmann collaborates with scholars based in United States, China and Spain. R. Brachmann's co-authors include Jef D. Boeke, Marc Vidal, Ed Harlow, Ali Fattaey, Georg Fuchs, S.W. Ragsdale, Colin D. Weekes, Carlos Gomez‐Roca, Alex A. Adjei and Jean‐Charles Soria and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Biochemistry.

In The Last Decade

R. Brachmann

16 papers receiving 589 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Brachmann United States	9	513	154	72	50	41	18	610
Cate Livingstone United Kingdom	3	417 0.8×	106 0.7×	70 1.0×	57 1.1×	67 1.6×	5	535
Sergei Fedorov United States	6	448 0.9×	170 1.1×	101 1.4×	83 1.7×	52 1.3×	10	637
L. Gutiérrez Venezuela	5	600 1.2×	129 0.8×	191 2.7×	31 0.6×	37 0.9×	25	740
Joshua Veatch United States	9	587 1.1×	319 2.1×	44 0.6×	48 1.0×	59 1.4×	20	956
Sharon Gauci Netherlands	8	475 0.9×	129 0.8×	51 0.7×	48 1.0×	37 0.9×	8	625
Danislav S. Spassov United States	14	449 0.9×	110 0.7×	66 0.9×	39 0.8×	65 1.6×	22	660
Thomas Tan United States	9	583 1.1×	224 1.5×	64 0.9×	49 1.0×	129 3.1×	11	682
Gina J. Fiala Germany	15	359 0.7×	167 1.1×	61 0.8×	31 0.6×	19 0.5×	23	654
C. Kenneth Kassenbrock United States	10	732 1.4×	77 0.5×	236 3.3×	41 0.8×	38 0.9×	10	881
Manjula Agarwal United States	9	699 1.4×	153 1.0×	80 1.1×	59 1.2×	116 2.8×	11	793

Countries citing papers authored by R. Brachmann

Since Specialization

Citations

This map shows the geographic impact of R. Brachmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Brachmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Brachmann more than expected).

Fields of papers citing papers by R. Brachmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Brachmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Brachmann. The network helps show where R. Brachmann may publish in the future.

Co-authorship network of co-authors of R. Brachmann

This figure shows the co-authorship network connecting the top 25 collaborators of R. Brachmann. A scholar is included among the top collaborators of R. Brachmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Brachmann. R. Brachmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Wu, Xiaohua, Jun Wang, Qi Zhou, et al.. (2018). Pamiparib, a novel PARP 1/2 inhibitor, monotherapy for gBRCAm patients with recurrent ovarian, fallopian, and primary peritoneal cancer: An open-label, multicenter, phase II trial in China. Annals of Oncology. 29. viii356–viii356. 1 indexed citations

Ciardiello, Fortunato, Yung‐Jue Bang, Johanna C. Bendell, et al.. (2018). A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy. Annals of Oncology. 29. viii265–viii265. 2 indexed citations

Ciardiello, Fortunato, Yung‐Jue Bang, Johanna C. Bendell, et al.. (2018). A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy - Trial in progress. Annals of Oncology. 29. v25–v26.

Weekes, Colin D., Heinz‐Josef Lenz, Bert H. O’Neil, et al.. (2016). Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC). Annals of Oncology. 27. vi117–vi117. 12 indexed citations

Messersmith, Wells A., S. Cohen, Safi Shahda, et al.. (2016). Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC). Annals of Oncology. 27. vi228–vi228. 16 indexed citations

Lolkema, Martijn P., Siew Hong Leong, G. Shankar, et al.. (2012). 365 A Phase 1b Open-label, Dose-escalation Study of the Safety and Pharmacology of GDC-0941 in Combination with Erlotinib in Patients with Advanced Solid Tumors. European Journal of Cancer. 48. 111–112. 2 indexed citations

Darbonne, Walter C., Xing Du, Punita Dhawan, et al.. (2011). Mechanism for platelet reduction in anti-neuropilin-1 (MNRP1685A)–treated phase I patients.. Journal of Clinical Oncology. 29(15_suppl). e13598–e13598. 10 indexed citations

Groen, Harry J.M., Alex A. Adjei, Grace K. Dy, et al.. (2011). 9012 POSTER DISCUSSION A Phase lb Study to Evaluate the PI3-Kinase Inhibitor GDC-0941 With Paclitaxel (P) and Carboplatin (C), With and Without Bevacizumab (BEV), in Patients With Advanced Non-small Cell Lung Cancer (NSCLC). European Journal of Cancer. 47. S595–S595. 1 indexed citations

Besse, Benjamin, Jean‐Charles Soria, Carlos Gomez‐Roca, et al.. (2011). A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 29(15_suppl). 3044–3044. 18 indexed citations

10.

Weekes, Colin D., P. LoRusso, L-Y Shih, et al.. (2011). A phase Ib study for MNRP1685A (anti-NRP1) administered intravenously with bevacizumab with or without paclitaxel to patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3050–3050. 11 indexed citations

11.

Patnaik, Amita, Colin D. Weekes, Priti S. Hegde, et al.. (2010). A phase Ib study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously in combination with bevacizumab with or without weekly paclitaxel in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). TPS180–TPS180. 2 indexed citations

12.

Weekes, Colin D., Priti S. Hegde, Xin Yan, et al.. (2010). A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3014–3014. 4 indexed citations

13.

Soria, Jean‐Charles, Carlos Gomez‐Roca, J. A. Ware, et al.. (2010). 421 A Phase Ib study to evaluate the pan-PI3K inhibitor GDC-0941 with paclitaxel and carboplatin with and without bevacizumab in non-small cell lung cancer patients. European Journal of Cancer Supplements. 8(7). 134–134. 4 indexed citations

14.

Danziger, Samuel A., S. Joshua Swamidass, Jue Zeng, et al.. (2006). Functional Census of Mutation Sequence Spaces: The Example of p53 Cancer Rescue Mutants. IEEE/ACM Transactions on Computational Biology and Bioinformatics. 3(2). 114–125. 24 indexed citations

15.

Brachmann, R., Marc Vidal, & Jef D. Boeke. (1996). Dominant-negative p53 mutations selected in yeast hit cancer hot spots.. Proceedings of the National Academy of Sciences. 93(9). 4091–4095. 136 indexed citations

16.

Vidal, Marc, R. Brachmann, Ali Fattaey, Ed Harlow, & Jef D. Boeke. (1996). Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-protein and DNA-protein interactions.. Proceedings of the National Academy of Sciences. 93(19). 10315–10320. 352 indexed citations

17.

Brachmann, R., et al.. (1995). Hydroxybenzoyl-CoA reductase: coupling kinetics and electrochemistry to derive enzyme mechanisms. Biochemistry. 34(37). 11668–11677. 14 indexed citations

18.

Brachmann, R., et al.. (1991). [Administration of prostaglandin E1 in diabetics and non-diabetic patients with severe Fontaine stage IIb arterial occlusive disease].. PubMed. 20(2). 100–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact